Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, ...
Contract Pharma14h
Teva and Samsung Bioepis Launch EPYSQLI in the U.S.
EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.
Healthline21d
Soliris (Eculizumab) Cost and Financial Assistance
The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...
Business Insider28d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...
pharmaphorum7d
Myasthenia Gravis approval will boost Soliris revenues
Soliris (eculizumab) earned $814 million in Q2, up 16% compared to the same period last year, based on its use in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome ...
Nature5y
How to make random mutagenesis less random
There is an approved treatment — a therapeutic antibody called eculizumab — but its half-life of only 11.3 days means patients need to endure transfusion every two weeks. In 2018, researchers ...